Fifty years of filler litigation show consent and regulatory status dictate liability

A retrospective review of US dermal filler civil litigation spanning 1967 to 2025 reveals that legal liability is driven primarily by regulatory and practice context rather than the severity of a patient's complication. Out of 46 cases analyzed, plaintiffs and defendants split final outcomes almost evenly, at 51% and 49% respectively. However, specific administrative failures practically guaranteed a loss in court. Procedures performed in medical spas carried a 100% plaintiff verdict rate, compared to 47% for those in private clinics or hospitals. Similarly, using unapproved fillers resulted in a 100% plaintiff verdict rate, whereas FDA-approved products saw a 44% rate. The single most critical protective factor for a practice was documented informed consent. When consent was documented, the plaintiff verdict rate dropped to just 8%, compared to 65% when documentation was missing. The specific filler type and the provider's credentials did not significantly impact liability. For practice owners, these findings mean that bulletproof consent paperwork and strict adherence to FDA-approved products are far more protective in court than credentials or even the severity of the clinical complication itself.

Source: Aesthetic Surgery Journal, https://doi.org/10.1093/asj/sjag168